Bayesian monitoring of clinical trials with failure-time endpoints

被引:16
|
作者
Rosner, GL [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA
关键词
clinical trials; Dirichlet process; Gibbs sampling; survival analysis;
D O I
10.1111/j.0006-341X.2005.031037.x
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
This article presents an aid for monitoring clinical trials with failure-time endpoints based on the Bayesian nonparametric analyses of the data. The posterior distribution is a mixture of Dirichlet processes in the presence of censoring if one assumes a Dirichlet process prior for the survival distribution. Using Gibbs sampling, one can generate random samples from the posterior distribution. With samples from the posterior distributions of treatment-specific survival curves, one can evaluate the current evidence in favor of stopping or continuing the trial based on summary statistics of these survival curves. Because the method is nonparametric, it can easily be used, for example, in situations where hazards cross or are suspected to cross and where relevant clinical decisions might be based on estimating when the integral between the curves might be expected to become positive and in favor of the new but toxic therapy. An example based on an actual trial illustrates the method.
引用
收藏
页码:239 / 245
页数:7
相关论文
共 50 条
  • [41] Endpoints in cancer clinical trials
    Fiteni, F.
    Westeel, V.
    Pivot, X.
    Borg, C.
    Vernerey, D.
    Bonnetain, F.
    [J]. JOURNAL OF VISCERAL SURGERY, 2014, 151 (01) : 17 - 22
  • [42] Endpoints of clinical trials in oncology
    Roila, F
    Del Favero, A
    Ballatori, E
    [J]. TUMORI JOURNAL, 1997, 83 (06): : S8 - S13
  • [43] Economic endpoints in clinical trials
    Cook, J
    Drummond, M
    Heyse, JF
    [J]. STATISTICAL METHODS IN MEDICAL RESEARCH, 2004, 13 (02) : 157 - 176
  • [44] CLINICAL TRIALS WITH BIOLOGICAL ENDPOINTS
    Roth, A. D.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 37 - 37
  • [45] ENDPOINTS FOR CLINICAL TRIALS OF SARCOIDOSIS
    Baughman, R. P.
    Drent, M.
    Culver, D. A.
    Grutters, J. C.
    Handa, T.
    Humbert, M.
    Judson, M. A.
    Lower, E. E.
    Mana, J.
    Pereira, C. A.
    Prasse, A.
    Sulica, R.
    Valyere, D.
    Vucinic, V.
    Wells, A. U.
    [J]. SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2012, 29 (02) : 90 - 98
  • [46] Surrogate Endpoints in Clinical Trials
    Elliott, Michael R.
    [J]. ANNUAL REVIEW OF STATISTICS AND ITS APPLICATION, 2023, 10 : 75 - 96
  • [47] METAANALYSIS OF FAILURE-TIME DATA WITH ADJUSTMENT FOR COVARIATES
    HUNINK, MGM
    WONG, JB
    [J]. MEDICAL DECISION MAKING, 1994, 14 (01) : 59 - 70
  • [48] A BIVARIATE WARNING-TIME/FAILURE-TIME DISTRIBUTION
    MIHRAM, GA
    HULTQUIS.RA
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1967, 62 (318) : 589 - &
  • [49] A Bayesian phase II proof-of-concept design for clinical trials with longitudinal endpoints
    Zhang, Wen
    Laird, Glen
    Chen, Josh
    Yuan, Ying
    [J]. STATISTICS IN MEDICINE, 2024, 43 (01) : 173 - 183
  • [50] Bayesian design and analysis of composite endpoints in clinical trials with multiple dependent binary outcomes
    Zaslavsky, Boris G.
    [J]. PHARMACEUTICAL STATISTICS, 2013, 12 (04) : 207 - 212